iCo Therapeutics Inc $ 0.05 -0.0029 (-5.8%)
Warning! GuruFocus has detected 1 Severe warning sign with ICOTF. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ICOTF (iCo Therapeutics Inc) from 2009 to Jan 22 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. iCo Therapeutics stock (ICOTF) PE ratio as of Jan 22 2021 is 0. More Details
iCo Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
iCo Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare TSXV:BCT TSXV:IOT TSXV:HEM TSXV:RP TSXV:PAS XCNQ:BUX TSXV:NSP TSX:IPCI TSXV:IBT TSXV:GENX OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.